Literature DB >> 30239792

Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.

Aya T Nanba1, Taweesak Wannachalee1,2, James J Shields3, James B Byrd4, William E Rainey1,5, Richard J Auchus1,6, Adina F Turcu1.   

Abstract

Context: Many antihypertensive medications modulate the renin-angiotensin-aldosterone system, possibly skewing the diagnosis and subtyping of primary aldosteronism (PA). Particularly, mineralocorticoid receptor antagonists (MRA) might raise renin and stimulate aldosterone synthesis from nonautonomous areas, potentially obscuring lateralization on adrenal vein sampling (AVS). Withdrawal of MRA in severe PA, however, can precipitate hypokalemia and/or hypertension and therefore is not always practical. Objective: To assess the effects of MRA on the interpretation of AVS data. Design and Participants: A cohort study of all PA patients who underwent AVS at University of Michigan between January 2009 and January 2018 was conducted. Demographics, diagnostic, AVS, surgical pathology, and follow-up data were collected retrospectively.
Results: Of 191 patients who underwent AVS, 51 (27%) were exposed to MRA at the time of the procedure. Plasma aldosterone concentration and the daily defined dose of antihypertensives were higher in patients taking vs those not taking MRA. Unilateral PA was more frequent in the MRA group, both precosyntropin and postcosyntropin (P < 0.05). The MRA group included two patients with unsuppressed renin, who demonstrated unequivocal AVS lateralization. To date, 86 patients underwent unilateral adrenalectomy, including 30 patients taking MRA during AVS. The proportion of clinical and biochemical success was not statistically different between patients exposed to and those not exposed to MRA during AVS (P = 0.17 and 0.65, respectively).
Conclusion: Our data suggest that conclusive AVS lateralization is often achieved in patients with severe PA despite MRA use.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30239792      PMCID: PMC6316984          DOI: 10.1210/jc.2018-01299

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism.

Authors:  Verena Fourkiotis; Oliver Vonend; Sven Diederich; Evelyn Fischer; Katharina Lang; Stephan Endres; Felix Beuschlein; Holger S Willenberg; Lars C Rump; Bruno Allolio; Martin Reincke; Marcus Quinkler
Journal:  Eur J Endocrinol       Date:  2012-12-10       Impact factor: 6.664

2.  Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism.

Authors:  Aya T Nanba; Kazutaka Nanba; James B Byrd; James J Shields; Thomas J Giordano; Barbara S Miller; William E Rainey; Richard J Auchus; Adina F Turcu
Journal:  Clin Endocrinol (Oxf)       Date:  2017-09-04       Impact factor: 3.478

3.  Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases.

Authors:  Yoshitsugu Iwakura; Ryo Morimoto; Masataka Kudo; Yoshikiyo Ono; Kei Takase; Kazumasa Seiji; Yoichi Arai; Yasuhiro Nakamura; Hironobu Sasano; Sadayoshi Ito; Fumitoshi Satoh
Journal:  J Clin Endocrinol Metab       Date:  2013-11-27       Impact factor: 5.958

4.  Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience.

Authors:  Norlela Sukor; Richard D Gordon; Yee Kim Ku; Mark Jones; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2009-04-28       Impact factor: 5.958

5.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

Authors:  John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2016-03-02       Impact factor: 5.958

6.  Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  Lancet Diabetes Endocrinol       Date:  2017-11-09       Impact factor: 32.069

7.  Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort.

Authors:  Tracy A Williams; Jacques W M Lenders; Paolo Mulatero; Jacopo Burrello; Marietta Rottenkolber; Christian Adolf; Fumitoshi Satoh; Laurence Amar; Marcus Quinkler; Jaap Deinum; Felix Beuschlein; Kanako K Kitamoto; Uyen Pham; Ryo Morimoto; Hironobu Umakoshi; Aleksander Prejbisz; Tomaz Kocjan; Mitsuhide Naruse; Michael Stowasser; Tetsuo Nishikawa; William F Young; Celso E Gomez-Sanchez; John W Funder; Martin Reincke
Journal:  Lancet Diabetes Endocrinol       Date:  2017-05-30       Impact factor: 32.069

Review 8.  New Advances in the Diagnostic Workup of Primary Aldosteronism.

Authors:  Martin J Wolley; Michael Stowasser
Journal:  J Endocr Soc       Date:  2017-01-27

9.  An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism.

Authors:  Gian Paolo Rossi; Richard J Auchus; Morris Brown; Jacques W M Lenders; Mitsuhide Naruse; Pierre Francois Plouin; Fumitoshi Satoh; William F Young
Journal:  Hypertension       Date:  2013-11-11       Impact factor: 10.190

10.  High-probability features of primary aldosteronism may obviate the need for confirmatory testing without increasing false-positive diagnoses.

Authors:  Gregory A Kline; Janice L Pasieka; Adrian Harvey; Benny So; Val C Dias
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-05-27       Impact factor: 3.738

View more
  7 in total

1.  Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.

Authors:  Yuta Tezuka; Adina F Turcu
Journal:  Endocr Pract       Date:  2020-12       Impact factor: 3.443

Review 2.  High Prevalence of Autonomous Aldosterone Production in Hypertension: How to Identify and Treat It.

Authors:  Taweesak Wannachalee; Leedor Lieberman; Adina F Turcu
Journal:  Curr Hypertens Rep       Date:  2022-02-14       Impact factor: 5.369

Review 3.  Primary aldosteronism - a multidimensional syndrome.

Authors:  Adina F Turcu; Jun Yang; Anand Vaidya
Journal:  Nat Rev Endocrinol       Date:  2022-08-31       Impact factor: 47.564

Review 4.  The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism.

Authors:  Piotr Jędrusik; Bartosz Symonides; Jacek Lewandowski; Zbigniew Gaciong
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

Review 5.  The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism.

Authors:  Gian Paolo Rossi; Valeria Bisogni; Alessandra Violet Bacca; Anna Belfiore; Maurizio Cesari; Antonio Concistrè; Rita Del Pinto; Bruno Fabris; Francesco Fallo; Cristiano Fava; Claudio Ferri; Gilberta Giacchetti; Guido Grassi; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Giuseppe Maiolino; Dario Manfellotto; Pietro Minuz; Silvia Monticone; Alberto Morganti; Maria Lorenza Muiesan; Paolo Mulatero; Aurelio Negro; Gianfranco Parati; Martino F Pengo; Luigi Petramala; Francesca Pizzolo; Damiano Rizzoni; Giacomo Rossitto; Franco Veglio; Teresa Maria Seccia
Journal:  Int J Cardiol Hypertens       Date:  2020-04-15

Review 6.  Evolution of the Primary Aldosteronism Syndrome: Updating the Approach.

Authors:  Anand Vaidya; Robert M Carey
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

7.  Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling.

Authors:  Adina F Turcu; Richard Auchus
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.